These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34088322)

  • 1. Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial.
    Park HJ; Kim SH; Shin YS; Park CH; Cho ES; Choi SJ; Park SH; Jung JH; Kang IG; Lee MS; Kim DW; Lee SM; Yang MS; Lee SP
    Respir Res; 2021 Jun; 22(1):170. PubMed ID: 34088322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.
    Skaarup SH; Schmid JM; Skjold T; Graumann O; Hoffmann HJ
    J Allergy Clin Immunol; 2021 Mar; 147(3):1011-1019. PubMed ID: 32679209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.
    Soyyigit S; Guloglu D; Ikinciogullari A; Secil D; Oztuna D; Mungan D; Misirligil Z; Sin BA
    Ann Allergy Asthma Immunol; 2016 Mar; 116(3):244-251.e2. PubMed ID: 26945497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis.
    Bozek A; Ignasiak B; Filipowska B; Jarzab J
    Clin Exp Allergy; 2013 Feb; 43(2):242-8. PubMed ID: 23331565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
    Hylander T; Latif L; Petersson-Westin U; Cardell LO
    J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intralymphatic allergen-specific immunotherapy].
    Næraa SH; Schollert NH; Flader Skov PN; Homøe P
    Ugeskr Laeger; 2018 May; 180(22):. PubMed ID: 29808813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralymphatic immunotherapy with one or two allergens renders similar clinical response in patients with allergic rhinitis due to birch and grass pollen.
    Ahlbeck L; Ahlberg E; Björkander J; Aldén C; Papapavlou G; Palmberg L; Nyström U; Retsas P; Nordenfelt P; Togö T; Johansen P; Rolander B; Duchén K; Jenmalm MC
    Clin Exp Allergy; 2022 Jun; 52(6):747-759. PubMed ID: 35332591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial.
    Rondón C; Campo P; Salas M; Aranda A; Molina A; González M; Galindo L; Mayorga C; Torres MJ; Blanca M
    Allergy; 2016 Jul; 71(7):1057-61. PubMed ID: 27008542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
    JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy.
    Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M
    Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralymphatic immunotherapy for mountain cedar pollinosis: A randomized, double-blind, placebo-controlled trial.
    Thompson CP; Silvers S; Shapiro MA
    Ann Allergy Asthma Immunol; 2020 Sep; 125(3):311-318.e2. PubMed ID: 32407947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
    J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
    Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
    Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study.
    Li J; Wu Y; Yang Y; Huang N; Li W; Zhang S; Jiang Q; Yang L; Zhu R
    Int Forum Allergy Rhinol; 2019 Aug; 9(8):876-882. PubMed ID: 31322838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial.
    Varney VA; Tabbah K; Mavroleon G; Frew AJ
    Clin Exp Allergy; 2003 Aug; 33(8):1076-82. PubMed ID: 12911781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
    Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
    J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis.
    Riechelmann H; Schmutzhard J; van der Werf JF; Distler A; Kleinjans HA
    Am J Rhinol Allergy; 2010; 24(5):e104-9. PubMed ID: 21244725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma].
    Yepes-Núñez JJ; Gómez C; Espinoza Y; Cardona R
    Biomedica; 2014; 34(2):282-90. PubMed ID: 24967933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.